GlycoMemetics (NASDAQ:GLYC)

CAPS Rating: 2 out of 5

Caps

How do you think GLYC will perform against the market?

Add Stock to CAPS Watchlist

All Players

40 Outperform
2 Underperform
 

All-Star Players

13 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top GLYC Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Andyman (83.61)
Submitted April 03, 2014

Love the science, management, and original investors.The two guys who originally designed the selectin inhibitors on which GLYC's drug candidates are based both still work for the company. The inhibitors will allow the company can develop and license… More

zzlangerhans (99.57)
Submitted March 31, 2015

I have a fairly straightforward problem with GlycoMimetics, which is that I think that their lead candidate rivipansel is dead and the share price has not declined to take this into account. Pfizer not initiated a phase III trial of rivipansel… More

GLYC VS S&P 500 (SPY)

GLYC Summary

Fools bullish on GLYC are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about GLYC.

Recs

0
Member Avatar clangmead (61.69) Submitted: 6/17/2018 8:00:15 AM : Outperform Start Price: $15.70 GLYC Score: +3.35

cash reserves

Recs

0
Member Avatar TMFEBCapital (88.90) Submitted: 12/18/2017 3:28:42 PM : Outperform Start Price: $16.37 GLYC Score: -3.72

Potential to reshape relapsing and recurring AML, improving outcomes and tolerability of existing chemotherapy regimens.

Recs

0
Member Avatar manirg (< 20) Submitted: 12/2/2014 8:41:39 AM : Outperform Start Price: $8.45 GLYC Score: +59.49

Undervalued

Leaderboard

Find the members with the highest scoring picks in GLYC.

Score Leader

drugtrader

drugtrader (93.52) Score: +367.82

The Score Leader is the player with the highest score across all their picks in GLYC.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
guillu 59.63 5/12/2017 Outperform NS $4.00 +312.00% +17.09% +294.91 0 Comment
mctracker1 66.97 3/7/2016 Outperform NS $5.25 +213.90% +40.44% +173.46 0 Comment
maxmeridius 68.76 5/19/2014 Outperform 5Y $6.45 +155.50% +49.16% +106.34 0 Comment
portefeuille 98.91 6/25/2014 Outperform 5Y $6.71 +145.60% +44.12% +101.48 0 Comment
portefeuille2 99.51 6/26/2014 3/6/2018 Outperform 5Y $6.76 +143.79% +43.12% +100.67 0 Comment
Halffrenzy 25.33 6/26/2014 Outperform 5Y $6.76 +143.79% +43.12% +100.67 0 Comment
dundara 89.22 9/6/2016 Outperform 1Y $7.22 +128.25% +28.01% +100.24 0 Comment
MacroHedge 48.91 6/9/2014 Outperform 5Y $6.87 +139.88% +43.11% +96.77 0 Comment
PayrollGeek 44.16 6/10/2014 Outperform 5Y $6.94 +137.46% +43.32% +94.14 0 Comment
portefeuille4 99.73 9/19/2014 Outperform 5Y $7.30 +125.75% +39.56% +86.19 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for GLYC.

Featured Broker Partners


Advertisement